Galderma Launches Twyneo Cream, the First Ever Tretinoin and Benzoyl Peroxide Combination

Posted By American Med Spa Association, Friday, April 1, 2022

Galderma announced today the U.S. launch of TWYNEO (tretinoin and benzoyl peroxide) Cream, 0.1%/3% at the American Academy of Dermatology (AAD) Annual Meeting, March 25-29, 2022, in Boston, Massachusetts. TWYNEO Cream is the first and only 0.1% tretinoin and 3% benzoyl peroxide (BPO) 2-in-1 combination proven to rapidly treat moderate to severe facial acne. Patented microencapsulation technology unites two ingredients that have not been previously combined and enables their controlled release to deliver visible results in as little as two weeks.

Acne is a widespread skin condition affecting 85% of Americans ages 12 to 24 that can trigger feelings of depression, poor body image and low self-esteem. Despite acne being common during this age, as many as 50% of teens have reported they experience unfair treatment at school because of their acne. Teens often fail multiple over-the-counter (OTC) acne treatment options before consulting a dermatology provider, despite 70% of parents wishing they sought specialist help sooner for their teen's acne.

"Effective prescription acne treatments currently involve multi-step regimens because there is rarely a single treatment option that addresses the multiple causes of the skin condition. These routines can often result in low adherence, especially among boys," said Caroline Robinson, MD, FAAD, Founder of Tone Dermatology. "TWYNEO Cream may help teens with acne – especially the boys –struggling with generic tretinoin or adhering to complex treatment routines, since it's a once-daily, potent combination that can be used any time of day."

In clinical trials,* some people saw results in as little as two weeks of using TWYNEO Cream, and their skin continued to clear over time. These studies demonstrated a 25 percent decrease in pimples at two weeks and a 58–66 percent decrease at 12 weeks; with 27–41 percent of people achieving clear or almost clear skin by the end of the trial. More than half of people who used TWYNEO Cream were satisfied at two weeks and by 12 weeks of treatment, 8 in 10 persons were satisfied with their results with 9 in 10 people staying on treatment until the end of the trial. TWYNEO Cream was well tolerated and side effects were mild to moderate and decreased over time. The most common side effects occurring in >2% of persons using TWYNEO Cream were application site pain, dryness, erythema (redness), and exfoliation.

Read more at PR Newswire >>